阿波利波蛋白E ε4在阿尔茨海默病中的影响:基于voxel的形态学研究的元分析
Madison Bailey1, Zlatomira G Ilchovska2,3, Akram A Hosseini1,4,5
1School of Medicine, University of Nottingham, Nottingham, UK.
Journal of clinical neurology (Seoul, Korea)
|September 3, 2024
概括
在阿波利波蛋白E (APOE) ε4基因基因显著增加海马缩在阿尔茨海默病 (AD) 和轻度认知障碍 (MCI). 这种遗传因素驱动神经退行,特别是在海马体,影响疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 放射学 放射学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,对个人和社会产生重大影响.
- 无脂蛋白E (APOE) ε4等位基因是已知AD的遗传风险因素,与大脑缩和症状严重程度的增加有关.
研究的目的:
- 综合审查APOE ε4等位基因对AD脑缩的影响.
- 检查APOE ε4对轻度认知障碍 (MCI) 脑缩的影响,这是AD的过渡阶段.
主要方法:
- 对基于voxel的形态测量研究进行了基于坐标的元分析.
- 灰质缩模式在APOE ε4载体和非载体之间进行了比较,使用了12项研究中的1,135人结构性MRI数据.
主要成果:
- 与非携带者相比,APOE ε4携带者表现出明显更大的海马体和准海马体缩.
- 这种效应在患有阿尔茨海默病和MCI的个体中尤为明显.
- 在这些地区,在健康对照载体中没有观察到显著的缩.
结论:
- 在AD和MCI中,APOE ε4等位基因与海马缩之间存在显著的关联.
- APOE ε4等位基因极大地影响神经退行,特别是在海马体内.
- 这些发现提高了对AD病理学的理解,有助于早期检测和个性化干预风险人群.
更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.7K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
相关概念视频
01:26Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170